Pembrolizumab monotherapy has been demonstrated as a first-line therapy for non-small-cell lung cancer (NSCLC) patients with a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) of ≥50%; however, the clinical efficacy is limited by the unreasonable threshold of the TPS. A recent study published by Mok et al. (Lancet 393:1819–1830, 2019) showed that pembrolizumab monotherapy could also be extended as an effective first-line therapeutic strategy for NSCLC patients with low TPS. However, this needs to be further evaluated in detail after considering the following issues. In Mok’s report, the survival curves were much lower in a pembrolizumab-treated group in the first 6 months of treatment compared with a chemotherapy group. These contradictory findings might have been due to anecdotal occurrences of rapid progression, especially hyperprogressive disease.

中文翻译：

---

派姆单抗作为非小细胞肺癌的一线单一疗法，其编程死亡配体1阈值较低。

Pembrolizumab单一疗法已被证明是编程性死亡配体1（PD-L1）肿瘤比例评分（TPS）≥50％的非小细胞肺癌（NSCLC）患者的一线治疗；但是，TPS的不合理阈值限制了临床疗效。Mok等人最近发表的一项研究。（柳叶刀393：1819–1830，2019）表明，派姆单抗也可以作为低TPS的NSCLC患者的有效一线治疗策略。但是，在考虑以下问题后，需要对此进行详细评估。在Mok的报告中，与化疗组相比，在用pembrolizumab治疗的组中，治疗的前6个月的生存曲线要低得多。这些矛盾的发现可能是由于轶事的快速发展所致，